Rabbit Polyclonal CYP2S1 Antibody

+ +

•  

   
     Western blot analysis of lysate from BEAS 2B cell line, using CYP2S1 Antibody (C-term)(Cat.  #P32656).  P32656 was diluted at 1:1000.  A goat anti-rabbit IgG H&L(HRP) at 1:5000 dilution was used as the secondary antibody. Lysate at 35ug.    

•  

   
     CYP2S1 Antibody (C-term) (Cat. #P32656) western blot analysis in HepG2 cell line lysates (35ug/lane).This demonstrates the CYP2S1 antibody detected the CYP2S1 protein (arrow).    

•  

   
     Confocal immunofluorescent analysis of CYP2S1 Antibody (C-term)(Cat#P32656) with HepG2 cell followed by Alexa Fluor® 488-conjugated goat anti-rabbit lgG (green). DAPI was used to stain the cell nuclear (blue).    

•  

   
     CYP2S1 Antibody (C-term) (Cat. #P32656)immunohistochemistry analysis in formalin fixed and paraffin embedded human stomach tissue followed by peroxidase conjugation of the secondary antibody and DAB staining.This data demonstrates the use of CYP2S1 Antibody (C-term) for immunohistochemistry.  Clinical relevance has not been evaluated.    

The CYP2S1 antibody is a crucial tool for studying the CYP2S1 enzyme, a member of the cytochrome P450 superfamily involved in metabolizing endogenous and exogenous compounds, including drugs, environmental toxins, and signaling molecules. Unlike other CYP isoforms predominantly expressed in the liver, CYP2S1 is widely detected in extrahepatic tissues, such as the skin, lungs, and gastrointestinal tract, suggesting roles in localized detoxification or bioactivation processes. It metabolizes retinoids, prostaglandins, and certain carcinogens, and has been implicated in inflammatory responses, cancer progression, and cellular oxidative stress regulation.

CYP2S1 antibodies enable researchers to detect and quantify the enzyme’s expression and localization in tissues or cell lines using techniques like Western blotting, immunohistochemistry (IHC), or immunofluorescence (IF). These antibodies are particularly valuable in cancer research, as CYP2S1 overexpression has been linked to tumor growth and chemoresistance in cancers such as colorectal and lung carcinoma. However, challenges persist in antibody specificity due to potential cross-reactivity with other CYP family members or splice variants. Validation using knockout controls or siRNA-mediated silencing is critical.

Commercially available CYP2S1 antibodies vary in host species, clonality, and epitope targets, requiring careful selection based on experimental needs. Ongoing studies aim to clarify CYP2S1’s physiological roles and its potential as a therapeutic target, underscoring the importance of reliable antibody tools in advancing this field.